Financial Review: ReNeuron Group (OTCMKTS:RNUGF) versus Central Japan Railway (OTCMKTS:CJPRY)

Earnings and Valuation

This table compares Central Japan Railway and ReNeuron Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Central Japan Railway	$11.85 billion	1.58	$2.66 billion	$1.48	6.41
ReNeuron Group	$640,000.00	0.10	-$6.52 million	N/A	N/A

Central Japan Railway has higher revenue and earnings than ReNeuron Group.

Profitability

This table compares Central Japan Railway and ReNeuron Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Central Japan Railway	19.65%	10.08%	4.49%
ReNeuron Group	N/A	N/A	N/A

Insider and Institutional Ownership

0.0% of Central Japan Railway shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Central Japan Railway has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, ReNeuron Group has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.

Summary

Central Japan Railway beats ReNeuron Group on 8 of the 8 factors compared between the two stocks.

About Central Japan Railway

Central Japan Railway Company engages in the railway and related businesses in Japan. The company operates through Transportation, Merchandise and Other, Real Estate, and Other segments. It primarily operates Tokaido Shinkansen, a transportation artery that links metropolitan areas of Tokyo, Nagoya, and Osaka, as well as a network of 12 conventional lines centered on the Nagoya and Shizuoka areas. The company also provides bus, logistics, travel agency, advertising, linen supply, track maintenance, construction and construction consulting, and contracted accounting and financial services; and manufactures and maintains railway rolling stock and machinery. In addition, it is involved in the operation of a department store; wholesale and retail sales business; sale of food and beverages; leasing and sale of real estate; hotel business; and development, improvement, and maintenance of computer systems. The company was incorporated in 1987 and is headquartered in Nagoya, Japan.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.